Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies.

A review of preclinical studies in animal models examines two emerging approaches for alcohol use disorder: psychedelics and epigenetic drugs (epidrugs). Both treatments show potential benefits for reducing alcohol drinking, seeking, motivation, and relapse. Because psychedelics and epidrugs may share common and complementary mechanisms of action, there is an opportunity for exploring synergies between these approaches and their parallel effectiveness in treating AUD and associated psychiatric conditions.

Study at a glance

Abstract

Alcohol use disorder (AUD) is a public health issue that affects millions of people worldwide leading to physical, mental and socio-economic consequences. While current treatments for AUD have provided relief to individuals, their effectiveness on the long term is often limited, leaving a number of affected individuals without sustainable solutions. In this review, we aim to explore two emerging approaches for AUD: psychedelics and epigenetic drugs (i.e., epidrugs). By examining preclinical studies, different animal species and procedures, we delve into the potential benefits of each of these treatments in terms of addictive behaviors (alcohol drinking and seeking, motivation to drink alcohol and prevention of relapse). Because psychedelics and epidrugs may share common and complementary mechanisms of action, there is an exciting opportunity for exploring synergies between these approaches and their parallel effectiveness in treating AUD and the diverse associated psychiatric conditions.